Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage Dysplasia

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 3, 2007, Pages 345-354

  Scott, Bart L ^a,b   Storer, Barry E ^a,b   Greene, Joanne E ^a   Hackman, Robert C ^a   Appelbaum, Frederick R ^a,b   Deeg, H Joachim ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Marrow fibrosis; Myelodysplastic syndrome; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; OVERALL SURVIVAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CELL LINEAGE; CHILD; CHILD, PRESCHOOL; DECISION MAKING; DELAYED GRAFT FUNCTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33847077565     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.030     Document Type: Article

References (56)

1. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
2. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103 (1985) 620-625
3. Jaffe E.S., Harris N.L., Stein H., et al. World Health Organization Classification of Tumours. Pathology & Genetics: Tumours of Hematopoietic and Lymphoid Tissues (2001), IARC Press, Washington, DC
4. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 2079-2088 Erratum 91:1100
5. Malcovati L., Germing U., Kuendgen A., et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood 106 (2005) 232a-233a (abstr.)
6. Verhoef G.E., De Wolf-Peeters C., Ferrant A., et al. Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 63 (1991) 235-241
7. Wells D.A., Benesch M., Loken M.R., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102 (2003) 394-403
8. Mangi M.H., and Mufti G.J. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies. Blood 79 (1992) 198-205
9. Steensma D.P., Hanson C.A., Letendre L., et al. Myelodysplasia with fibrosis: a distinct entity?. Leuk Res 25 (2001) 829-838
10. Michels S.D., McKenna R.W., Arthur D.C., et al. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 65 (1985) 1364-1372
11. Tricot G., De Wolf-Peeters C., Hendrickx B., et al. Bone marrow histology in myelodysplastic syndromes: I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol 57 (1984) 423-430
12. Cunningham I., MacCallum S.J., Nicholls M.D., et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol 90 (1995) 602-606
13. Lambertenghi-Deliliers G., Orazi A., Luksch R., et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 78 (1991) 161-166
14. Maschek H., Georgii A., Kaloutsi V., et al. Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol 48 (1992) 208-214
15. Lambertenghi-Deliliers G., Annaloro C., Oriani A., et al. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes. Ann Hematol 66 (1993) 85-91
16. Cassano E., Giordano M., Riccardi A., et al. Myelodysplastic syndromes: a multiparametric study of prognostic factors and a proposed scoring system. Haematologica 75 (1990) 141-145
17. Buesche G., Georgii A., Duensing A., et al. Evaluating the volume ratio of bone marrow affected by fibrosis: a parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol 34 (2003) 391-401
18. Noren-Nystrom U., Roos G., Bergh A., et al. Prognostic impact of vascular density and fibrosis in the bone marrow of children with high-risk acute lymphoblastic leukemia. Leukemia 19 (2005) 1998-2001
19. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
20. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
21. Manoharan A. Myelofibrosis: prognostic factors and treatment. Br J Haematol 69 (1988) 295-298
22. Manoharan A., Horsley R., and Pitney W.R. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 43 (1979) 185-190
23. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
24. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan before transplantation of allogeneic hematopoietic stem cells. Blood 100 Part 1 (2002) 213a (abstr.)
25. Anderson J.E., Appelbaum F.R., Fisher L.D., et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 82 (1993) 677-681
26. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
27. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002) 161-169
28. Mickelson E., and Petersdorf E.W. Histocompatibility. In: Blume K.G., Forman S.J., and Appelbaum F.R. (Eds). Thomas' Hematopoietic Cell Transplantation (2004), Blackwell, Oxford, UK 31-42
29. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
30. Przepiorka D., Weisdorf D., Martin P., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
31. Sullivan K.M., Shulman H.M., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 57 (1981) 267-276
32. Flowers M.E.D., Traina F., Storer B., et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning. Bone Marrow Transplant 35 (2005) 277-282 Erratum 35;535
33. Nash R.A., Furlong T., Storb R., et al. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis. Blood 90 Suppl 1 (1997) 105a (abstr.)
34. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (Rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72 (2001) 1924-1929
35. Carpenter P.A., Appelbaum F.R., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 (2002) 2712-2719
36. Durnam D.M., Anders K.R., Fisher L., et al. Analysis of the origin of marrow cells in bone marrow transplant recipients using a Y chromosome-specific in situ hybridization assay. Blood 74 (1989) 2220-2226
37. Scharf S.J., Smith A.G., Hansen J.A., et al. Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 85 (1995) 1954-1963
38. Ugozzoli L., Yam P., Petz L.D., et al. Amplification by the polymerase chain reaction of hypervariable regions of the human genome for evaluation of chimerism after bone marrow transplantation. Blood 77 (1991) 1607-1615
39. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95 (2000) 1188-1194
40. Sievers E.L., Lange B.J., Buckley J.D., et al. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 88 (1996) 1483-1488
41. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
42. Gooley T.A., Martin P.J., Fisher L.D., et al. Simulation as a design tool for phase I/II clinical trials: an example from bone marrow transplantation. Control Clin Trials 15 (1994) 450-462
43. Cox D.R. Regression models and life tables (with discussion). J Royal Stat Soc B 34 (1972) 187-220
44. Sierra J., Pérez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
45. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
46. Deeg H.J., Gooley T.A., Flowers M.E.D., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
47. Rajantie J., Sale G.E., Deeg H.J., et al. Adverse effect of severe marrow fibrosis on hematological recovery after chemoradiotherapy and allogeneic bone marrow transplantation. Blood 67 (1986) 1693-1697
48. Soll E., Massumoto C., Clift R.A., et al. Relevance of marrow fibrosis in bone marrow transplantation: a retrospective analysis of engraftment. Blood 86 (1995) 4667-4673
49. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
50. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
51. Jacobson R.J., Salo A., and Fialkow P.J. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51 (1978) 189-194
52. Awaya N., Rupert K., Bryant E., et al. Marrow stromal cells are not derived from the malignant clone in myelodysplastic syndromes (MDS). Blood 98 Part 1 (2001) 353a (abstr.)
53. Terui T., Niitsu Y., Mahara K., et al. The production of transforming growth factor-beta in acute megakaryoblastic leukemia and its possible implications in myelofibrosis. Blood 75 (1990) 1540-1548
54. Yanagida M., Ide Y., Imai A., et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 99 (1997) 739-745
55. Martyre M.C., Le Bousse-Kerdiles M.C., Romquin N., et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97 (1997) 441-448
56. Kimura A., Katoh O., Hyodo H., et al. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts. Br J Haematol 72 (1989) 486-491